DMS Imaging (LTS:0RGO) Debt-to-Asset : 0.41 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging Debt-to-Asset?

DMS Imaging's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.06 Mil. DMS Imaging's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.86 Mil. DMS Imaging's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €43.76 Mil. DMS Imaging's debt to asset for the quarter that ended in Dec. 2023 was 0.41.

DMS Imaging Debt-to-Asset Historical Data

The historical data trend for DMS Imaging's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging Debt-to-Asset Chart

DMS Imaging Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.72

1.03

0.35

0.37

0.41

DMS Imaging Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.35	0.36	0.37	0.42	0.41

Competitive Comparison of DMS Imaging's Debt-to-Asset

For the Biotechnology subindustry, DMS Imaging's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMS Imaging's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where DMS Imaging's Debt-to-Asset falls into.

DMS Imaging Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

DMS Imaging's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.058	+	11.863)	/	43.758
	=	0.41

DMS Imaging's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.058	+	11.863)	/	43.758
	=	0.41

DMS Imaging (LTS:0RGO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

DMS Imaging Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of DMS Imaging's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

DMS Imaging (LTS:0RGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (LTS:0RGO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AS0:Germany ALIMG:Belgium

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (LTS:0RGO) Headlines

No Headlines